Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium.

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. No abstract available.

2.

Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015.

Dinmohamed AG, Issa DE, van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED, Zweegman S, Visser O.

Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26. No abstract available.

3.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

4.

Emergence of carbapenemase-producing Acinetobacter ursingii in The Netherlands.

Sieswerda E, Schade RP, Bosch T, de Vries J, Chamuleau MED, Haarman EG, Schouls L, van Dijk K.

Clin Microbiol Infect. 2017 Oct;23(10):779-781. doi: 10.1016/j.cmi.2017.04.024. Epub 2017 May 6. No abstract available.

PMID:
28487169
5.

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, d'Amore F, Haioun C, Thieblemont C, González-Barca E, García CG, Johnson PW, van Imhoff GW, Ng T, Dwyer K, Morschhauser F.

Haematologica. 2016 Oct;101(10):e407-e410. Epub 2016 Jul 14. No abstract available.

6.

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP.

Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15.

PMID:
26878656
7.

Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.

de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, van Maanen T, Lindauer-van der Werf G, Beeker A, Timmers GJ, Schaar CG, Soesan M, Poddighe PJ, de Jong D, Chamuleau ME.

Eur J Cancer. 2016 Mar;55:140-6. doi: 10.1016/j.ejca.2015.12.001. Epub 2016 Jan 25. Review.

PMID:
26820684
8.

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2015 Jun;100(6):e220-2. doi: 10.3324/haematol.2014.116657. Epub 2015 Mar 6. No abstract available.

9.

18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.

Wondergem MJ, Rizvi SN, Jauw Y, Hoekstra OS, Hoetjes N, van de Ven PM, Boellaard R, Chamuleau ME, Cillessen SA, Regelink JC, Zweegman S, Zijlstra JM.

J Nucl Med. 2015 Feb;56(2):216-21. doi: 10.2967/jnumed.114.149625. Epub 2015 Jan 15.

10.

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.

Issa DE, van de Schans SA, Chamuleau ME, Karim-Kos HE, Wondergem M, Huijgens PC, Coebergh JW, Zweegman S, Visser O.

Haematologica. 2015 Apr;100(4):525-33. doi: 10.3324/haematol.2014.107300. Epub 2014 Dec 15.

11.

ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.

Wiggers TG, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, Poddighe P, van de Loosdrecht AA, Chamuleau ME.

Cytometry B Clin Cytom. 2014 Jul;86(4):280-7. doi: 10.1002/cyto.b.21132. Epub 2013 Oct 8.

12.

Cyclosporin in cell therapy for cardiac regeneration.

Jansen Of Lorkeers SJ, Hart E, Tang XL, Chamuleau ME, Doevendans PA, Bolli R, Chamuleau SA.

J Cardiovasc Transl Res. 2014 Jul;7(5):475-82. doi: 10.1007/s12265-014-9570-8. Epub 2014 May 16. Review.

13.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25.

PMID:
24731748
14.

ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.

Wiggers TG, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, Poddighe P, van de Loosdrecht AA, Chamuleau ME.

Cytometry B Clin Cytom. 2013 Oct 1. doi: 10.1002/cytob.21132. [Epub ahead of print]

15.

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party.

Neth J Med. 2013 Mar;71(2):54-62.

16.

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.

van Luijn MM, Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA, Marieke van Ham S.

Oncoimmunology. 2012 Mar 1;1(2):211-213.

17.

Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011.

Kater AP, Wittebol S, Chamuleau ME, van Gelder M, J van Oers MH, Hovon CLL Working Party.

Neth J Med. 2011 Oct;69(10):422-9. Review.

18.

Catastrophic antiphospholipid syndrome in the obstetric period.

Thielen N, Bolte AC, Zweegman S, Chamuleau ME.

Eur J Obstet Gynecol Reprod Biol. 2012 Feb;160(2):237-8. doi: 10.1016/j.ejogrb.2011.09.047. Epub 2011 Oct 24. No abstract available.

PMID:
22030072
19.

Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

van Luijn MM, Westers TM, Chamuleau ME, van Ham SM, Ossenkoppele GJ, van de Loosdrecht AA.

Am J Pathol. 2011 Nov;179(5):2157-61. doi: 10.1016/j.ajpath.2011.07.027. Epub 2011 Sep 9.

20.

Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.

van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Cancer Res. 2011 Apr 1;71(7):2507-17. doi: 10.1158/0008-5472.CAN-10-3689. Epub 2011 Feb 10.

21.

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.

Chamuleau ME, Ossenkoppele GJ, van Rhenen A, van Dreunen L, Jirka SM, Zevenbergen A, Schuurhuis GJ, van de Loosdrecht AA.

Leuk Res. 2011 Jun;35(6):741-9. doi: 10.1016/j.leukres.2010.12.032. Epub 2011 Feb 1.

22.

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM.

Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5.

23.

Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.

van Luijn MM, van den Ancker W, Chamuleau ME, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Immunotherapy. 2010 Jan;2(1):85-97. doi: 10.2217/imt.09.84. Review.

PMID:
20635891
24.

Monoclonal antibody therapy in haematological malignancies.

Chamuleau ME, van de Loosdrecht AA, Huijgens PC.

Curr Clin Pharmacol. 2010 Aug;5(3):148-59. Review.

PMID:
20406175
25.

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.

Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA.

Blood. 2010 Mar 4;115(9):1779-84. doi: 10.1182/blood-2009-08-239749. Epub 2009 Dec 28.

26.

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA.

Haematologica. 2010 Mar;95(3):485-93. doi: 10.3324/haematol.2009.010595. Epub 2009 Nov 10.

27.

Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.

Souwer Y, Chamuleau ME, van de Loosdrecht AA, Tolosa E, Jorritsma T, Muris JJ, Dinnissen-van Poppel MJ, Snel SN, van de Corput L, Ossenkoppele GJ, Meijer CJ, Neefjes JJ, Marieke van Ham S.

Br J Haematol. 2009 May;145(3):334-43. doi: 10.1111/j.1365-2141.2009.07625.x. Epub 2009 Feb 24.

PMID:
19245431
28.

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Chamuleau ME, Westers TM, van Dreunen L, Groenland J, Zevenbergen A, Eeltink CM, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2009 Apr;94(4):496-506. doi: 10.3324/haematol.13612. Epub 2009 Feb 19.

29.

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, Valk PJ, Löwenberg B, Ossenkoppele GJ.

Haematologica. 2008 Dec;93(12):1894-8. doi: 10.3324/haematol.13113. Erratum in: Haematologica. 2009 Aug;94(8):1182.

30.

MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation.

Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA.

Immunobiology. 2006;211(6-8):619-25. Epub 2006 Jul 7. Review.

PMID:
16920500
31.

Mixed autoimmune haemolysis in a SLE patient due to aspecific and anti-Jka autoantibodies; case report and review of the literature.

Wondergem MJ, Overbeeke M, Som N, Chamuleau ME, Jonkhoff AR, Zweegman S.

Haematologica. 2006 May;91(5 Suppl):ECR12. Review. No abstract available.

32.

Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.

Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ.

Cancer Res. 2004 Aug 15;64(16):5546-50. Erratum in: Cancer Res. 2004 Oct 1;64(19):7181.

33.
34.

Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro.

Parlevliet KJ, Chamuleau ME, Yong SL, Raasveld MH, ten Berge IJ, Schellekens PT.

Clin Exp Immunol. 1995 Feb;99(2):155-9.

35.

Serum levels of soluble CD27 in renal transplant recipients.

Chamuleau ME, ten Berge IJ, Schellekens PT, Wilmink JM, Hintzen RQ, van Lier RA.

Transplantation. 1992 Nov;54(5):932-6. No abstract available.

PMID:
1332227

Supplemental Content

Loading ...
Support Center